In clinical trials, people who took semaglutide lost an average of 15% of their body weight over 1 year
But what we rarely see is upstream work It's this often invisible but essential element that gives these effects their real meaning
While litigation involving these drugs is ongoing, the claims have raised important questions about how GLP-1 medications affect the digestive system and what patients should know about potential risks
In the phase 2 trial published in the New England Journal of Medicine , participants on the 12 mg dose lost an average of 24.2% of their body weight in just 48 weeks
There has been increasing interest in the FDA-approved GLP-1 agonist semaglutide (Ozempic, Wegovy), which is approved for the treatment of diabetes and weight loss, but may also have beneficial effects for reducing alcohol and drug intake
Lose the weight and keep it off naturally